

Chen Qu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5525061/publications.pdf>

Version: 2024-02-01

15
papers

531
citations

759233

12
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

877
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1568-1582.	3.6	21
2	Myofibroblast-specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model. <i>Hepatology</i> , 2021, 74, 458-473.	7.3	15
3	EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3. <i>Cell Death and Disease</i> , 2020, 11, 830.	6.3	17
4	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. <i>Function</i> , 2020, 1, .	2.3	12
5	Pyruvate Kinase M2 Tetramerization Protects against Hepatic Stellate Cell Activation and Liver Fibrosis. <i>American Journal of Pathology</i> , 2020, 190, 2267-2281.	3.8	32
6	Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness. <i>Cancer Cell International</i> , 2020, 20, 586.	4.1	30
7	Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1062-1074.	7.7	29
8	Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis. <i>PLoS ONE</i> , 2020, 15, e0233702.	2.5	19
9	RCE1 deficiency enhances invasion via the promotion of epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 7236-7248.	0.0	1
10	Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. <i>Hepatology</i> , 2018, 68, 1125-1139.	7.3	74
11	<scp>RPA</scp> 3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2872-2883.	3.6	38
12	An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. <i>Cancer Medicine</i> , 2017, 6, 310-319.	2.8	80
13	RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. <i>Cell Death and Disease</i> , 2016, 7, e2352-e2352.	6.3	58
14	BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro. <i>Radiation Oncology</i> , 2015, 10, 123.	2.7	26
15	Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 49-58.	3.6	79